US Stock MarketDetailed Quotes

AMLX Amylyx Pharmaceuticals

Watchlist
  • 5.270
  • +0.080+1.54%
Close Nov 22 16:00 ET
  • 5.230
  • -0.040-0.76%
Post 19:49 ET
361.25MMarket Cap-1379P/E (TTM)

About Amylyx Pharmaceuticals Company

Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). Its commercial product is Relyvrio, also known as Albrioza in Canada. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Company Profile

SymbolAMLX
Company NameAmylyx Pharmaceuticals
Listing DateJan 7, 2022
Issue Price19.00
Founded2013
MarketNASDAQ
Employees384
Fiscal Year Ends12-31
Address43 Thorndike Street
CityCambridge
ProvinceMassachusetts
CountryUnited States of America
Zip Code02141
Phone1-617-682-0917
Websitehttp://www.amylyx.com

Company Executives

  • Name
  • Position
  • Salary
  • Justin Klee
  • Co-Chief Executive Officer and Director
  • 7.42M
  • Joshua Cohen
  • Co-Chief Executive Officer and Director
  • 7.42M
  • James M. Frates
  • Chief Financial Officer and Principal Accounting Officer
  • 3.51M
  • Gina M. Mazzariello
  • Chief Legal Officer and General Counsel
  • 3.01M
  • Dr. Camille L. Bedrosian,M.D.
  • Chief Medical Officer
  • 2.37M
  • Dr. George Mclean Milne, Jr,PhD
  • Chairman of the Board
  • 385.07K
  • Dr. Bernhardt G. Zeiher, F.A.C.P.,F.C.C.P.,M.D.
  • Director
  • --
  • Daphne E. Quimi
  • Independent Director
  • 348.59K
  • Karen Firestone
  • Independent Director
  • 681.15K
  • Paul Fonteyne, M.S.
  • Independent Director
  • 342.12K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data